BRONS + TEN KATE 11/8/22 BRONS + TEN KATE 11/8/22 VectorY Appoints Sander van Deventer as CEO and makes Key Appointments to its Leadership Team Read More BRONS + TEN KATE 10/26/22 BRONS + TEN KATE 10/26/22 VectorY to Participate in the Jefferies and JP Morgan Healthcare Conferences Read More BRONS + TEN KATE 10/7/22 BRONS + TEN KATE 10/7/22 VectorY Announces Participation in Scientific Conferences in October 2022 Read More BRONS + TEN KATE 8/23/22 BRONS + TEN KATE 8/23/22 VectorY to Present Poster on Huntington’s Preclinical Data at the Hereditary Disease Foundation, August 24-27 in Cambridge, MA Read More BRONS + TEN KATE 6/15/22 BRONS + TEN KATE 6/15/22 Cell & Gene Meeting on the Med 2022 & Cell & Gene Meeting on the Mesa 2021 Read More BRONS + TEN KATE 5/20/22 BRONS + TEN KATE 5/20/22 VectorY presents 2 posters on the pre-clinical development of VTx-001 and VTx-002 at the American Society of Gene and Cell Therapy Congress 2022 Annual Meeting, May 16-19 in Washington, D.C. Read More BRONS + TEN KATE 5/18/22 BRONS + TEN KATE 5/18/22 VectorY is participating in a large cureQ consortium named “Predict, Delay & Cure polyglutamine(Q) caused neurodegeneration”. Read More BRONS + TEN KATE 5/18/22 BRONS + TEN KATE 5/18/22 VectorY Announces Preclinical Data on TDP-43 and Oxidized Phospholipids at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting Read More BRONS + TEN KATE 1/26/22 BRONS + TEN KATE 1/26/22 VectorY and Wageningen University sign strategic collaboration for the development of novel baculovirus-based AAV production technologies Read More BRONS + TEN KATE 8/17/21 BRONS + TEN KATE 8/17/21 Assembling a new gene therapy company to develop the next generation of pioneering medicines Read More BRONS + TEN KATE 6/15/21 BRONS + TEN KATE 6/15/21 VectorY raises €31 million in seed financing to develop next-generation gene therapies aimed at muscular and CNS disorders Read More BRONS + TEN KATE 6/15/21 BRONS + TEN KATE 6/15/21 VectorY strengthens leadership with appointments of new CEO and CTO Read More BRONS + TEN KATE 5/21/21 BRONS + TEN KATE 5/21/21 VectorY presents at ASGCT 2021 about advances and challenges of vectorized antibodies for the treatment of neuromuscular diseases. Read More BRONS + TEN KATE 4/13/21 BRONS + TEN KATE 4/13/21 VectorY have been selected as winners of the Merck Millipore 2021 European Advance Biotech Program! Read More BRONS + TEN KATE 2/10/21 BRONS + TEN KATE 2/10/21 Launch of novel gene therapy company, VectorY, to develop innovative vectorized antibodies Read More
BRONS + TEN KATE 11/8/22 BRONS + TEN KATE 11/8/22 VectorY Appoints Sander van Deventer as CEO and makes Key Appointments to its Leadership Team Read More
BRONS + TEN KATE 10/26/22 BRONS + TEN KATE 10/26/22 VectorY to Participate in the Jefferies and JP Morgan Healthcare Conferences Read More
BRONS + TEN KATE 10/7/22 BRONS + TEN KATE 10/7/22 VectorY Announces Participation in Scientific Conferences in October 2022 Read More
BRONS + TEN KATE 8/23/22 BRONS + TEN KATE 8/23/22 VectorY to Present Poster on Huntington’s Preclinical Data at the Hereditary Disease Foundation, August 24-27 in Cambridge, MA Read More
BRONS + TEN KATE 6/15/22 BRONS + TEN KATE 6/15/22 Cell & Gene Meeting on the Med 2022 & Cell & Gene Meeting on the Mesa 2021 Read More
BRONS + TEN KATE 5/20/22 BRONS + TEN KATE 5/20/22 VectorY presents 2 posters on the pre-clinical development of VTx-001 and VTx-002 at the American Society of Gene and Cell Therapy Congress 2022 Annual Meeting, May 16-19 in Washington, D.C. Read More
BRONS + TEN KATE 5/18/22 BRONS + TEN KATE 5/18/22 VectorY is participating in a large cureQ consortium named “Predict, Delay & Cure polyglutamine(Q) caused neurodegeneration”. Read More
BRONS + TEN KATE 5/18/22 BRONS + TEN KATE 5/18/22 VectorY Announces Preclinical Data on TDP-43 and Oxidized Phospholipids at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting Read More
BRONS + TEN KATE 1/26/22 BRONS + TEN KATE 1/26/22 VectorY and Wageningen University sign strategic collaboration for the development of novel baculovirus-based AAV production technologies Read More
BRONS + TEN KATE 8/17/21 BRONS + TEN KATE 8/17/21 Assembling a new gene therapy company to develop the next generation of pioneering medicines Read More
BRONS + TEN KATE 6/15/21 BRONS + TEN KATE 6/15/21 VectorY raises €31 million in seed financing to develop next-generation gene therapies aimed at muscular and CNS disorders Read More
BRONS + TEN KATE 6/15/21 BRONS + TEN KATE 6/15/21 VectorY strengthens leadership with appointments of new CEO and CTO Read More
BRONS + TEN KATE 5/21/21 BRONS + TEN KATE 5/21/21 VectorY presents at ASGCT 2021 about advances and challenges of vectorized antibodies for the treatment of neuromuscular diseases. Read More
BRONS + TEN KATE 4/13/21 BRONS + TEN KATE 4/13/21 VectorY have been selected as winners of the Merck Millipore 2021 European Advance Biotech Program! Read More
BRONS + TEN KATE 2/10/21 BRONS + TEN KATE 2/10/21 Launch of novel gene therapy company, VectorY, to develop innovative vectorized antibodies Read More
